The company, spun out of Google’s DeepMind in 2021, develops an AI drug-design engine built from simulation models that examine different areas of chemistry. Its work draws on DeepMind’s AlphaFold protein-folding system. Isomorphic said its programs have produced “positive preclinical results” in oncology and immunology, and it has signed deals with Eli Lilly, Novartis and Johnson & Johnson.
The new capital follows a $2.1 billion Series B round in May. Isomorphic said it will use the funds to keep developing its drug-design engine and expand into more types of medicine. Existing backers GV and Capital G, Alphabet’s venture divisions, also took part, alongside Thrive Capital, MGX, Temasek and the UK Sovereign AI Fund.
The round is Isomorphic’s first since founder and CEO Demis Hassabis stepped down as head of DeepMind to focus on drug discovery and moved into a chairman role there. Hassabis and then-DeepMind director John Jumper won the Nobel Prize in chemistry for work on AlphaFold, which predicts a protein’s three-dimensional structure from its genetic sequence.
Isomorphic did not disclose its valuation. Bloomberg reported earlier this month that the company was seeking funding at a $50 billion valuation.

Comments (0)
No comments yet. Be the first!